| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Product revenue, net | 287,268 | 212,802 | 137,250 | 62,175 |
| Cost of sales | 18,122 | 9,065 | 4,513 | 2,152 |
| Research and development | 174,004 | 54,081 | 44,172 | 68,742 |
| Selling, general and administrative | 209,117 | 196,858 | 167,876 | 107,585 |
| Total operating expenses | 401,243 | 260,004 | 216,561 | 178,479 |
| Loss from operations | -113,975 | -47,202 | -79,311 | -116,304 |
| Interest income | 10,308 | 8,227 | 9,370 | 13,019 |
| Interest expense | 7,451 | 3,264 | - | - |
| Loss on extinguishment of debt | -2,779 | - | - | - |
| Interest expense | - | - | 3,297 | 3,679 |
| Other expense, net | -293 | -42 | - | - |
| Net loss | -114,190 | -42,281 | -73,238 | -106,964 |
| Basic net loss per common share (in dollars per share) | -5.08 | -1.9 | -3.32 | -4.92 |
| Basic weighted average number of common shares outstanding (in shares) | 22,482,502 | 22,207,017 | 22,091,314 | 21,745,929 |
| Diluted net loss per common share (in dollars per share) | -5.08 | -1.9 | -3.32 | -4.92 |
| Diluted weighted average number of common shares outstanding (in shares) | 22,482,502 | 22,207,017 | 22,091,314 | 21,745,929 |
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
MADRIGAL PHARMACEUTICALS, INC. (MDGL)